A Phase III Long Term Study of K-877 Extended Release Tablet
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 121 participants.
Also called NCT04716595
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 121 participants
- Sponsor
- Registry
-
NCT04716595
-
- Other papers using this trial's data
- Long-Term Effects of Extended-Release Pemafibrate Tablets on Dyslipidemia and Safety in Triglyceridemic Patients: A Phase 3, Multicenter, Randomized, Open-Label, Parallel-Group Study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT04716595. Randomized; no masking; primary purpose treatment. Start 2021-02-01 (actual); primary completion 2022-06-13 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase III Long Term Study of K-877 Extended Release Tablet
- Condition
- Dyslipidemias
- Intervention (Drug)
- K-877 ER 0.2 mg/day morning administration (once daily)
- Intervention (Drug)
- K-877 ER 0.2 mg/day evening administration (once daily)
- Lead sponsor
- Kowa Company, Ltd.
Record details
- Record id
cardio:ct-nct04716595- Content hash
e6a26ba72ef14c294bd5383fd1bd8facaa919f789c8d3bd9b2357d78733551da